Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynairgen Regulatory News (SNG)

  • There is currently no data for SNG

Total Voting Rights

30 Jun 2009 09:56

RNS Number : 7642U
Synairgen plc
30 June 2009
 



30 June 2009

Synairgen plc

("Synairgen" or "the Company")

Total Voting Rights

 

For the purposes of the Financial Services Authority's disclosure and Transparency Rules, the Company's total issued share capital at the date of this notice is 59,745,249. 

The Company's issued share capital consists of 59,745,249 ordinary shares of 1p each, with one voting right per share. There are no shares held in treasury.

The total number of voting rights in the Company is therefore 59,745,249.

The above figure of 59,745,249 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the Disclosure and Transparency Rules.

For more information please contact:

 

Synairgen plc  Tel: + 44 (0) 2380 512 800

Richard Marsden, Managing Director

John Ward, Finance Director

Matrix Corporate Capital  Tel: + 44 (0) 20 3206 7000

Alastair Stratton

Anu Tayal

Threadneedle Communications  Tel: + 44 (0) 20 7653 9850

Graham Herring

Josh Royston

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TVRCKKKPFBKKAAN
Date   Source Headline
3rd Jun 201911:52 amRNSResult of AGM
18th Apr 20199:20 amRNSDirectorate Change, Annual Report & Notice of AGM
5th Apr 201912:55 pmRNSGrant of Options
14th Mar 20197:00 amRNSPositive DSMC Review of Phase II Study for SNG001
25th Feb 20197:00 amRNSPreliminary results for the year ended 31 Dec 2018
17th Jan 20198:31 amRNSUpdate on LOXL2 programme with Pharmaxis
22nd Oct 201810:05 amRNSHolding(s) in Company
22nd Oct 20187:00 amRNSPart 2 start of Phase II COPD trial
16th Oct 20183:01 pmRNSHolding(s) in Company
15th Oct 20188:49 amRNSHolding(s) in Company
12th Oct 201811:05 amRNSResult of General Meeting
12th Oct 201810:29 amRNSResult of General Meeting
25th Sep 20185:56 pmRNSResult of Fundraise
25th Sep 20181:01 pmRNSProposed Fundraise to raise c.£2.9 million
25th Sep 20181:00 pmRNSHalf-year Report
28th Jun 20187:00 amRNSPositive SNG001 Biomarker Data in COPD Patients
26th Jun 20181:05 pmRNSHolding(s) in Company
22nd Jun 201811:42 amRNSResult of AGM
22nd Jun 20187:00 amRNSSynairgen Safety Data with SNG001 in COPD Patients
17th May 20187:00 amRNSPosting of Annual Report and Notice of AGM
16th Apr 20184:29 pmRNSHolding(s) in Company
6th Apr 201812:14 pmRNSGrant of Options
3rd Apr 20185:21 pmRNSHolding(s) in Company
15th Mar 20183:13 pmRNSIssue of Equity
15th Mar 20183:11 pmRNSHolding(s) in Company
15th Mar 20187:00 amRNSPreliminary results for year ended 31 Dec 2017
7th Feb 20187:00 amRNSSynairgen starts dosing in Phase II COPD study
14th Dec 20177:00 amRNSUpdate on LOXL2 Programme&Pharmaxis Collaboration
8th Nov 20174:31 pmRNSHolding(s) in Company
27th Sep 20177:00 amRNSInterim results for six months ended 30 June 2017
27th Sep 20177:00 amRNSData update and clinical plan for COPD
13th Sep 201712:44 pmRNSHolding(s) in Company
6th Sep 20177:00 amRNSLOXL2 Inhibitor Update.
28th Jun 201712:41 pmRNSResult of AGM
5th Jun 20177:00 amRNSPosting of Annual Report and Notice of AGM
17th May 20177:00 amRNSPreliminary Results
27th Apr 20177:00 amRNSAZD9412 Update
27th Mar 20177:00 amRNSHolding(s) in Company
13th Mar 20173:10 pmRNSHolding(s) in Company
10th Mar 20178:34 amRNSAdditional Positive Data in Lung Fibrosis
17th Jan 20172:46 pmRNSHolding(s) in Company
13th Oct 201610:44 amRNSHolding(s) in Company
12th Oct 20167:00 amRNSAZD9412 Clinical Trial Update
22nd Sep 20167:00 amRNSInterim results for six months ended 30 June 2016
8th Sep 20167:00 amRNSNotice of Interim Results
14th Jun 201612:00 pmRNSResult of AGM
17th May 20167:00 amRNSPosting of Annual Report and Notice of AGM
21st Apr 20162:14 pmRNSHolding(s) in Company
23rd Mar 20167:00 amRNSExercise of Options
22nd Mar 20167:00 amRNSPreliminary results for the year ended 31 Dec 2015

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.